When will the first RISUG procedure become commercially available?
RegulaciónOne-OffSalud y medicina4aManifold MarketsSin KYCDatos de resolución verificadosCalibración aceptablePronóstico comunitario actual2035 or later 55.2%Líder entre 11 opciones
Pronosticadores
2
Tipo de pregunta
multiple choice
Metodología
Play-money forecasting platform
Tipo de fuente
Pronóstico
Cambio 7d
0.0 pts
Datos de mercado
Actualizado hace 15 horas
Desactualizado30 jun 25, 13:25 UTC30 dic 30, 14:21 UTC
Tendencias
Mercados Relacionados
Preguntas relacionadas para dar contexto, no una comparación de contratos equivalentes.
In what year will Tesla's robotaxi become commercially operational in the US?
Manifold MarketsWill there be a commercially available LLM-based self-driving system by EoY 2030?
Manifold MarketsWill a useful contact lens display be commercially available by 2030
Manifold MarketsWill we have AGI before commercially available and viable flying cars???
Manifold MarketsWill all covid vaccines be pulled off the market before 2030?
Manifold MarketsWhich engineering breakthroughs will achieve widespread commercial and societal integration by 2050? [add responses]
Manifold MarketsReglas
Resolution Criteria
- This market will resolve to the first year in which the Reversible Inhibition of Sperm Under Guidance (RISUG) procedure becomes commercially available to the general public. "Commercially available" is defined as the procedure being offered by licensed medical practitioners outside of clinical trial settings, with necessary regulatory approvals in place.
- The resolution will be based on official announcements from regulatory bodies or reputable medical institutions confirming the availability of RISUG for public use.
- RISUG is a non-hormonal male contraceptive developed in India, involving an injection into the vas deferens to block sperm transport.
- Clinical trials have demonstrated its efficacy and safety, with a reported 97% success rate in preventing pregnancy.
- As of 2023, RISUG has completed Phase III clinical trials in India and is awaiting regulatory approval from the Drug Controller General of India (DCGI).
